NASDAQ:ATHX - Athersys Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.41 0.00 (0.00 %)
(As of 01/18/2019 08:32 AM ET)
Previous Close$1.41
Today's Range$1.40 - $1.44
52-Week Range$1.29 - $3.09
Volume290,626 shs
Average Volume522,736 shs
Market Capitalization$199.86 million
P/E Ratio-4.86
Dividend YieldN/A
Beta0.03
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATHX
CUSIPN/A
Phone216-431-9900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.71 million
Book Value$0.20 per share

Profitability

Net Income$-32,240,000.00
Net Margins-108.83%

Miscellaneous

Employees66
Market Cap$199.86 million
OptionableOptionable

Athersys (NASDAQ:ATHX) Frequently Asked Questions

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.01. The biopharmaceutical company earned $2.32 million during the quarter, compared to the consensus estimate of $1.80 million. Athersys had a negative return on equity of 58.74% and a negative net margin of 108.83%. View Athersys' Earnings History.

When is Athersys' next earnings date?

Athersys is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Athersys.

What price target have analysts set for ATHX?

1 equities research analysts have issued 1 year price targets for Athersys' stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Athersys' share price to reach $6.00 in the next twelve months. This suggests a possible upside of 325.5% from the stock's current price. View Analyst Price Targets for Athersys.

What is the consensus analysts' recommendation for Athersys?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Athersys.

What are Wall Street analysts saying about Athersys stock?

Here are some recent quotes from research analysts about Athersys stock:
  • 1. According to Zacks Investment Research, "Athersys, Inc., a late stage biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused primarily on treating critical care indications neurological conditions, cardiovascular diseases, inflammatory and immune disorders, pulmonary and other conditions. The company's lead platform product is MultiStem cell therapy, an off the shelf allogeneic stem cell product currently in Phase 3 clinical development for treating ischemic stroke. Based on promising Phase 2 results, this program has received Fast Track and RMAT (equivalent to Breakthrough Therapy for regenerative medicine treatments) designations from the FDA, as well as similar designations in Japan. The company also has an ongoing Phase II clinical study for treating patients with acute myocardial infarction; a planned Phase II for trauma (supported by the DOD). " (1/16/2019)
  • 2. Maxim Group analysts commented, "Athersys reported 2Q18 with $19.4M in revenue, which includes $18.5M related to the expanded partnership with Helios (6927JP – NR). With operating expenses just over $12M, the company ended the period with net income of $6.9M, as well as $53.4M in cash on the balance sheet." (8/8/2018)

Has Athersys been receiving favorable news coverage?

News articles about ATHX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Athersys earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days.

Who are some of Athersys' key competitors?

Who are Athersys' key executives?

Athersys' management team includes the folowing people:
  • Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 57)
  • Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 52)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 51)
  • Ms. Laura K. Campbell, Sr. VP of Fin. (Age 54)
  • Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.41.

How big of a company is Athersys?

Athersys has a market capitalization of $199.86 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.

What is Athersys' official website?

The official website for Athersys is http://www.athersys.com.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]


MarketBeat Community Rating for Athersys (NASDAQ ATHX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  246 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  460
MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel